Skip to main content

Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump

Roche lowered its 2024 growth outlook in February as it continues to confront a drop-off in demand for its Covid-19 products and a number of its cancer drugs.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.